Control Of A "Blind" Neuroreceptor With An Optical Switch
Main Category: Eye Health / BlindnessAlso Included In: Neurology / Neuroscience
Article Date: 12 Jan 2012 - 0:00 PST
When nerve cells communicate with one another, specialized receptor molecules on their surfaces play a central role in relaying signals between them. A collaborative venture involving teams of chemists based at Ludwig-Maximilians-Universität (LMU) in Munich and the University of California in Berkeley has now succeeded in converting an intrinsically "blind" receptor molecule into a photoreceptor. They achieved this feat by using molecular genetic techniques to attach what amounts to a light-controlled chemical "switch" to a macromolecular receptor that is normally activated by the endogenous neurotransmitter acetylcholine. Dirk Trauner, Professor of Chemical Biology and Genetics at LMU Munich, who played a leading role in the project, hopes that the synthetic construct will help to elucidate the precise roles of the natural receptor in the brain. Indeed, he says that it might ultimately be possible to use such synthetic photoreceptors to restore sight to patients suffering from certain forms of blindness (Nature Chemistry, 8.1.2012).
Trauner and his colleagues chose one of the so-called nicotinic acetylcholine receptors for their experiments. These molecular machines transmit nerve impulses essentially by converting an incoming chemical signal into an electrical response, which is propagated along the length of the nerve fiber. They are found in many types of excitable cells in the nervous system, and at the so-called "endplates" which form the functional connections between muscle cells and the motor nerves that control them. Such receptors span the cell membrane, forming a physical link between the external medium and the interior of the cell. Binding of the neurotransmitter acetylcholine to the external surface of the receptor acts as a switch, opening a tiny pore in the receptor, through which positively charged sodium ions can flow into the cell. The resulting depolarization (change in the balance between positive and negative charges on either side of the membrane) gives rise to the so-called action potential, the basic electrical stimulus that constitutes the neural response.
The functional features of neuroreceptors make them attractive targets for a research strategy that Trauner calls "optochemical genetics." This involves the use of genetic manipulation to modify a receptor protein so that it can bind a synthetic, light-sensitive switching ligand. Compounds known as azobenzenes can serve as the basis for such switching elements. They contain a photosensitive double bond between nitrogen atoms, and can be flipped between bent and extended conformations by illumination with monochromatic light of different wavelengths. In order to ensure that the artificial switch attaches at the correct position, and that the light-induced conformational changes are sufficient to open and close the ion channel, Trauner and his colleagues introduced several targeted modifications into the gene that specifies the amino acid sequence of the receptor. Using electrophysiological techniques, they were able to confirm that cultured cells expressing the mutated gene responded in the expected manner. Following incubation of the cells with the appropriate azobenzene compound, illumination with violet light was shown to activate the modified receptor, while subsequent exposure to green light closed its ion channel.
The project was carried out in the context of the Collaborative Research Center (SFB) on "Formation and Function of Neuronal Circuits in Sensory Systems," which is funded by the German Research Foundation (DFG). In 2010 Dirk Trauner received one of the highly endowed Advanced Grants awarded by the European Research Council (ERC) for a project which is also based on a "photopharmacological" approach. Its long-term goal is to find ways of compensating for the loss of dedicated photoreceptors in the eye - the most common cause of blindness. To achieve this goal, Trauner is working on the development of hybrid photoreceptors. "The basic idea, which has in principle been shown to work in animal models, is to confer light sensitivity on surviving neurons in the eye that do not normally respond to light," he says.
Visit our eye health / blindness section for the latest news on this subject.
Optochemical control of genetically targeted neuronal nicotinic acetylcholine receptors
I. Tochitsky, M.R. Banghart, A. Mourot, J.Z. Yao, B. Gaub, R.H. Kramer, D. Trauner
Nature Chemistry, 8.1.2012 doi: 10.1038/NCHEM.1234
Ludwig-Maximilians-Universität München
MLA
23 Feb. 2012. <http://www.medicalnewstoday.com/releases/240185.php>
APA
http://www.medicalnewstoday.com/releases/240185.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Visitor Opinions In Chronological Order (1)
Short cut over Implants
posted by Dave on 13 Jan 2012 at 3:37 pmThis idea has ben around for several years, mainly based on rhodopsin varieties to induce sensitivity in ganglion and other non sensitive neurotransmitters in the retina. No trials in humans, but mice seem to respond to a light source. It seems less invasive and cheaper than planned electronic implants. It does not seem to progress commercially. A concentrated focus would be an economical target, without the wasteful non co-operative intrigues going on at present.
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




